Downregulation of SLC7A7 Triggers an Inflammatory Phenotype in Human Macrophages and Airway Epithelial Cells

Bianca Maria Rotoli1, Amelia Barilli1, Rossana Visigalli1, Filippo Ingoglia1, Marco Milioli2, Maria Di Lascia2, Benedetta Riccardi2, Paola Puccini2 and Valeria Dall’Asta1*

1 Department of Medicine and Surgery (DiMeC), University of Parma, Parma, Italy, 2 Preclinical Pharmacokinetics, Biochemistry and Metabolism Department, Chiesi Farmaceutici, Parma, Italy

Lysinuric protein intolerance (LPI) is a recessively inherited aminoaciduria caused by mutations of SLC7A7, the gene encoding y+LAT1 light chain of system y+L for cationic amino acid transport. The pathogenesis of LPI is still unknown. In this study, we have utilized a gene silencing approach in macrophages and airway epithelial cells to investigate whether complications affecting lung and immune system are directly ascribable to the lack of SLC7A7 or, rather, mediated by an abnormal accumulation of arginine in mutated cells. When SLC7A7/y+LAT1 was silenced in human THP-1 macrophages and A549 airway epithelial cells by means of short interference RNA (siRNA), a significant induction of the expression and release of the inflammatory mediators IL1β and TNFα was observed, no matter the intracellular arginine availability. This effect was mainly regulated at transcriptional level through the activation of NFκB signaling pathway. Moreover, since respiratory epithelial cells are the important sources of chemokines in response to pro-inflammatory stimuli, the effect of IL1β has been addressed on SLC7A7 silenced A549 cells. Results obtained indicated that the downregulation of SLC7A7/ y+LAT1 markedly strengthened the stimulatory effect of the cytokine on CCL5/RANTES expression and release without affecting the levels of CXCL8/IL8. Consistently, also the conditioned medium of silenced THP-1 macrophages activated airway epithelial cells in terms of CCL5/RANTES expression due to the presence of elevated amount of proinflammatory cytokines. In conclusion, our results point to a novel thus far unknown function of SLC7A7/y+LAT1, that, under physiological conditions, besides transporting arginine, may act as a brake to restrain inflammation.

Keywords: LPI, innate immunity, cytokine and chemokines, inflammation, arginine

INTRODUCTION

Lysinuric protein intolerance (LPI; MIM 222700) is a recessively inherited aminoaciduria caused by mutations of SLC7A7, the gene encoding y+LAT1 light chain of system y+L for cationic amino acid transport (1, 2). LPI is a severe multisystem disorder characterized by protein-rich food intolerance with secondary urea cycle disorders; symptoms are heterogeneous and include failure...
to thrive, recurrent vomiting, episodes of hyperammonemic coma after a protein-rich meal, hepatosplenomegaly, muscular hypotonia, osteoporosis, lung involvement, kidney failure, hematologic abnormalities, and immunological disorders with autoimmunity (3).

The physiopathology of LPI is thus far only partially elucidated. The classical hallmarks of the disease, i.e., leakage of cationic amino acids in the urine and normal-to-low plasma levels, are directly ascribable to a defective intestinal absorption of the amino acids, combined with an increased loss in the kidney due to SLC7A7/y+LAT1 mutation in the basolateral membrane of intestinal and renal epithelial cells (4-7); the resulting deficiency of urea cycle intermediates in blood leads to a functional impairment of the cycle that easily explains hyperammonemia and, in turn, acute symptoms after protein ingestion, such as nausea and vomiting (8). Conversely, a nutritional imbalance in LPI patients cannot give reason of the complex multiorgan manifestations of the disease that represent the major causes of morbidity and mortality.

As for lung complications, LPI patients frequently manifest with progressive pulmonary tissue changes typical of interstitial lung disease (ILD) (9), a collection of disorders characterized by inflammation and fibrosis in the lung. Traditionally, pulmonary fibrotic processes were considered a chronic inflammatory-driven response caused by the abnormal accumulation of inflammatory cells, such as alveolar macrophages, but current evidence suggests that the fibrotic response could also be driven by abnormally activated airway epithelial cells (10). In LPI, in particular, a well-known life-threatening complication of ILD is the progression to severe pulmonary alveolar proteinosis (PAP) with an excessive deposition of surfactant-like lipoproteinaeous material within alveoli, which often accounts for the fatal outcome due to respiratory failure (11). In addition, LPI associates with an increased incidence of hemophagocytic lymphohistiocytosis (HLH) (12, 13), a wide array of related life-threatening conditions in which uncontrolled and self-sustained activation of lymphocytes and macrophages leads to a severe hyper-inflammatory state. A variety of disease mechanisms can lead to HLH: while primary forms, also known as familial HLH, are caused by genetic defects that impair lymphocytes’ cytotoxic function, acquired HLH are secondary to infections, autoimmune and autoinflammatory diseases, malignancy or metabolic disorders such as LPI (14). In both cases, an excessive cytokine production (“cytokine storm”) occurs, due to the over-activation of macrophages and cytotoxic lymphocytes that infiltrate tissues, leading to multiorgan dysfunction and, ultimately, to an increased mortality (15). Moreover, clinical and biochemical findings consistent with systemic lupus-like syndromes have been also reported in LPI patients (3, 16, 17), suggesting a role for immune dysfunctions in the onset of the disease; systemic lupus erythematous (SLE) is, indeed, a chronic and complex autoimmune condition that leads to widespread inflammation and tissue injury in multiple organs (18).

Although the pathogenetic mechanisms of LPI and its complications are still unclear, the involvement of the mononuclear phagocyte system is nowadays well recognized. Indeed, the case of an LPI patient has been reported, who underwent heart-lung transplantation for severe PAP-associated respiratory insufficiency, relapsed and died of respiratory failure after a period of clinical remission (19), suggesting that circulating cells, likely monocytes/macrophages, colonized the transplanted lung and reproduced the pathological condition. Moreover, experimental evidence obtained by our and other groups demonstrated that monocytes/macrophages typically express high levels of SLC7A7 (20) and that LPI macrophages display an impaired phagocytosis (21), as well as dysfunctions in toll-like receptor signaling (22).

In light of these findings, it has been speculated that immunological complications of LPI could be ascribable to alterations of bone marrow-derived monocytes that make them differentiating into dysfunctional macrophages. More precisely, since y+LAT1 operates as an efflux route for arginine (23), LPI defect is expected to cause an abnormal accumulation of the amino acid inside the cells (21, 23); hence, Sebastio et al. proposed that immune dysfunctions in LPI may be due to alterations of arginine intracellular metabolic routes in mononuclear cells, with an hyper-induction of the pro-inflammatory pathway of nitric oxide synthase (3). Although this hypothesis appears intriguing, we explore here the possibility that y+LAT1 protein is endowed with thus far unknown immunomodulatory functions and that SLC7A7 mutation, besides affecting arginine transport and intracellular availability, also directly modulates the inflammatory phenotype of macrophages and airway epithelial cells.

MATERIALS AND METHODS

Cell Models and Cultures

THP-1 cells (ATCC® TIB-202™) were cultured in arginine-free RPMI1640 medium (Biochrom AG, Germany) added with different concentrations of the amino acid (0.1, 1.0, and 10 mM); the medium was supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin and cells were routinely maintained in suspension under exponential growth at a density ranging from 2 × 10^5 to 1 × 10^6 cells/ml, with serial passages in culture flasks (Falcon, Steroglass, Italy). For the experiments, cells underwent gene silencing of SLC7A7/y+LAT1, as already described (23). Briefly, a suspension of cells (1.5 × 10^6/ml) was diluted with an equal volume of serum free RPMI1640 containing HiPerFect Transfection Reagent (Qiagen®, Italy; 30 µl/ml) and 60 nM scrambled (AllStar Negative Control; Qiagen®, Cat.# SI03650318) or SLC7A7 (FlexiTube short interfering RNA; Qiagen®; Cat.# SI00058660) siRNA; after 4 h cell suspension was further diluted 1:3 with fresh, complete culture medium. After 24 h, cells were induced to differentiate by addition of phorbol-12-myristate-13-acetate (PMA; 80 nM) and maintained in culture for further 72 h. When caspase-1 inhibition was required, 10 µM z-WHED-FMK (R&D System, Space, Italy) was added 1 h before the addition of PMA. When indicated, the incubation medium of THP-1 cells was employed as conditioned medium (CM) for the treatment of A549 cells (see below).

Human pulmonary epithelial A549 cells (ATCC® CCL-185™) were routinely cultured in Dulbecco’s Modified Eagle Medium (DMEM, high glucose) supplemented with sodium
pyruvate (1 mM), 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin. When gene silencing was required, cells were transfected according to the fast-forward transfection protocol provided by the manufacturer (Qiagen®): cells (1 × 10⁶/ ml) were transfected by adding 0.2 volume of serum-free medium containing HiPerFect Transfection Reagent (9 µl/ml) and 100 nM scrambled or SLC7A6/y+LAT2 (FlexiTube short interfering RNA; Qiagen®, Cat.# SI00058681) siRNA; transfected cells were seeded as required by the experimental plan and maintained under growing conditions for 96 h.

RT-qPolymerase Chain Reaction

1 µg of total RNA, isolated with GenElute™ Mammalian Total RNA Miniprep Kit (Sigma, Italy), was reverse transcribed and 40 ng of cDNA was amplified as described previously (20) with the following primers (5 pmol each): 5’ CCA GCA GTC GTC TTT GTC AC 3’ and 5’ TTC TGG GTC ACA ACA CAT TCT 3’ for CCL5/RANTES; 5’ ACT GAG AGT GAT TGA GAG TGG AC 3’ and 5’ AAC CCT CTG CAC CCA CCA TTC 3’ for CXCL8/IL8; 5’ ACA GAC CCT CCA GGA GAA TG 3’ and 5’ GCA GTT CAG TAC AG 3’ for IL1B; and 5’ ATG AGC ACT GAA AGC ACT ATG AAC CCT CTG CAC CCA GTT TTC 3’ and 5’ GAG GGC TGA TTA GAG AGA GGT C 3’ for TNFA. The expression of SLC7A6/y+LAT2, SLC7A7/ y+LAT1 and that of the housekeeping gene RPL15 (Ribosomal Protein Like 15) were monitored employing specific TaqMan® Gene Expression Assays (Life Technologies Italia, Milano, Italy; Cat# Hs00187757_m1, Hs00909952_m1, and Hs03855120_g1, respectively), according to the manufacturer's instructions. The expression of the gene of interest under each experimental condition was normalized to that of the housekeeping gene, according to the comparative CT method (ΔΔCT Method) (24), and shown as “fold increase” with respect to its levels in cells transfected with scrambled siRNA (= 1).

L-Arginine Influx

Four distinct mechanisms, named systems y⁺, y⁻L, b⁰⁺, and B⁰⁺, account for arginine transport in mammalian tissues (see (25) for review); their contribution to total uptake can be discriminated on the basis of their differential sensitivity to inhibition by neutral amino acids in the absence or in the presence of sodium (25).

For the characterization of arginine transport in alveolar cells, A549 cells were cultured onto 96-well trays (Falcon). After two rapid washes in pre-warmed transport buffer [Earle’s Balanced Salt Solution, EBSS, containing (in mM) 117 NaCl, 1.8 CaCl₂, 5.3 KCl, 0.9 NaH₂PO₄, 0.8 MgSO₄, 5.5 glucose, 26 Tris/ HCl, adjusted to pH 7.4], cells were incubated for 1 min in the same solution containing [¹⁵N]arginine (50 µM, 5 µCi/ml) in the absence or presence of 2 mM leucine or 2 mM leucine + lysine, so as to discriminate the contribution of systems y⁺L and y⁻L. When sodium-independent transport was to be measured, a modified Na⁺-free EBSS (NMG-EBSS) was employed, with NaCl and NaH₂PO₄ replaced by N-methyl-d-glucamine and choline salts, respectively. The experiment was terminated by two rapid washes (<10 s) in ice-cold 300 mM urea. The intracellular pool of cell monolayers was extracted in ethanol, and radioactivity in cell extracts was determined with Wallac Microbeta Trilux liquid scintillation spectrometer (PerkinElmer, Italy). L-Arginine uptake was normalized for protein content, determined directly in each well by using a modified Lowry procedure (26) and expressed as pmol/mg of protein/min. Since an excess of neutral amino acids inhibits system y⁺L activity while an excess of leucine and lysine hinders all saturable components, the contribution of systems y⁻L was calculated as the difference between total uptake and the uptake obtained in the presence of 2 mM leucine, and system y⁺ activity was calculated as the difference between the uptake measured in the presence of 2 mM leucine and in presence of 2 mM leucine + lysine.

Determination of Arginine Intracellular Content

For the determination of the intracellular content of arginine, cells were rapidly washed with PBS and the intracellular pool, extracted with a 10 min-incubation in acetonitrile/water (1:1) at 4°C, was analyzed by HPLC-ESI-MS/MS as previously described (27), with minor modifications. Briefly, HPLC separation was carried out on Ascentis Express HILIC column (Supelco, Bellefonte, PA, USA) at 35°C. Analytes (injection volume corresponding to 10 µl) were chromatographically separated under optimized gradient; mass spectrometric analyses were carried out using an AB SCIEX 4500 Q-TRAP (AB Sciex, Foster City, CA, USA) with a Turbo Ion Spray probe in positive mode. The monitored transitions for l-arginine and ¹⁵N₂-Arginine (used as internal standard) were 174.739 m/z → 70.031 m/z and 176.739 m/z → 70.031 m/z, respectively. Protein content in each condition was determined using a modified Lowry procedure (28) and l-arginine content was expressed as nmol/mg of protein.

Determination of Cytokine and Chemokine Production

Cell culture supernatants were collected under the indicated experimental conditions, centrifuged for 10 min at 250 g and kept at −20°C for the measurements of cytokines and chemokines. IL1β, IL8, RANTES, and TNFα in the extracellular medium were, then, quantified using Quantikine ELISA kit (R&D System), Human IL8 Picokine ELISA Kit (Vinci Biochem), Human RANTES ELISA Kit (MyBioSource), and Human TNFα ELISA Kit (ImmunoLical Sciences), respectively. All measurements were made following manufacturers’ instructions.

Determination of Caspase-1 Activity

The activation of caspase-1 was monitored in THP-1 cell lysates by employing the commercially available Caspase-1/ICE Colorimetric Assay Kit by R&D System, according to the manufacturer’s instruction.

Western Blot Analysis

The expression of y+LAT2 and y+LAT1 proteins was determined in whole protein lysates obtained as already described (23), while the activation of NF-kB pathway was monitored in nuclear extracts isolated with the Nuclear Extract Kit (Active Motif, Vinci-Biochem, Italy); Western Blot analyses were, then, performed as described previously (23). Briefly, 20 µg of proteins were separated by SDS-PAGE (10% acrylamide) and electrophoretically...
transferred to PVDF membranes (Immobilon-P membrane; Millipore, Italy). Membranes were incubated for 1 h at RT in Tris-buffered saline solution (TBS; 50 mM Tris-HCl pH 7.5, 150 mM NaCl) containing 5% non-fat dried milk, then incubated overnight at 4°C in TBS added with 3% non-fat dried milk and anti-NF-κB p65 (1:1000; Santa Cruz Biotechnology, Italy), anti-y+LAT2, or anti-y+LAT1 (1:500; Thermo Fisher Scientific, Italy) antibodies. PARP or α-actin, detected with polyclonal antibodies (1:1000; Cell Signaling Technology, EuroClone, Italy or Sigma Aldrich, respectively), was employed as internal standard. Immunoreactivity was visualized with enhanced chemiluminescence (Millipore).

**Statistics**

Statistical analysis has been performed with Prism®5.0 GraphPad software. Gaussian distribution has been preliminary verified; then parametric tests have been employed to calculate statistical significance, as specified for each figure. Differences were considered significant when \( p < 0.05 \).

**Materials**

Endotoxin-free fetal bovine serum (FBS) was purchased from EuroClone (Italy); l-[2,3,4-3H]Arginine monohydrochloride (43 Ci/mmol) was obtained from Perkin-Elmer (Italy) and GM-CSF from Vinci-Biochem (Italy). Unless otherwise stated, Sigma-Aldrich (Italy) was the source of all the other chemicals.

**RESULTS**

**SLC7A7 Gene Silencing Induces a Pro-Inflammatory Pathway in THP-1 Macrophages**

In order to reproduce in vitro the genetic defect of LPI macrophages, SLC7A7/y+LAT1 was silenced by means of short interference RNA (siRNA) in PMA-differentiated human THP-1 cells (Figure 1). A significant decrease of mRNA and protein expression was observed in THP-1 cells after 72 h gene silencing (Figure 1A), as previously reported (23). Under the same experimental conditions, arginine intracellular content was slightly, but significantly higher in silenced (SLC7A7 siRNA) than in control (scrambled siRNA) cells (Figure 1B). Interestingly, the decrease of SLC7A7 expression was paralleled by the simultaneous induction of a pro-inflammatory phenotype in treated macrophages: a significant increase of the mRNAs coding for interleukin 1β (IL1β) and tumor necrosis factor-alpha (TNFα) was, indeed, observed upon gene silencing (Figure 1C), along with an increased release of the same cytokines in the incubation medium (Figure 1D).

In light of these findings, we next explored whether the acquisition of an inflammatory behavior by macrophages upon SLC7A7 silencing was directly caused by the lack of y+LAT1 protein or, rather, mediated by intracellular arginine. To address this issue, THP-1 cells were cultured in the presence of different concentrations (0.1, 1, and 10 mM) of extracellular arginine, so as to modulate the intracellular amount of the amino acid (Figure 2). As shown in Figure 2A, arginine progressively accumulated inside the cells as its concentrations in the extracellular medium increased; however, no change in the expression of either IL1B (Figure 2B) or TNFA (Figure 2C) genes was observed. Moreover, SLC7A7 silencing at any concentration of arginine (Figure 2D) caused a significant increase of the mRNAs coding for IL1β (Figure 2E) and TNFα (Figure 2F), no matter the amount of the amino acid; the observed induction was comparable under the different experimental conditions despite the big differences in intracellular arginine content. These findings demonstrate that the acquired inflammatory behavior in SLC7A7 silenced cells is independent from arginine content.

The release of IL1β has been described as a two-step process involving (1) the NFκB-dependent transcription of the gene for the synthesis of the inactive 31-kDa pro-IL1β and (2) the cleavage of pro-IL1β into the biologically active 17-kDa IL1β protein through the inflammasome-dependent activation of caspase-1 (29). Hence, we evaluated the activity of both NF-κB and caspase-1 under our experimental conditions, so as to define the mechanism responsible for the release of IL1β observed in THP-1 cells upon SLC7A7 silencing. As shown in Figure 3, the inhibition of caspase-1 by Z-WEHD-FMK during the transfection had no effect on IL1B mRNA expression.
(Figure 3A), while it completely prevented the increase of cytokine secretion (Figure 3B); however, the activity of caspase-1 was comparable in THP-1 cells transfected with scrambled or SLC7A7 siRNA (Figure 3C), suggesting that gene silencing had no or, at most, slight effect on the induction of enzyme activity. Conversely, a higher translocation of the NF-κB subunit p65 inside the nucleus was observed upon gene silencing (Figure 3D), indicating that the induction of IL1β secretion due to SLC7A7 downregulation in macrophages is regulated at transcriptional level through the activation of NF-κB-dependent mechanisms.

**SLC7A7 Gene Silencing Strengthens IL1β-Driven Inflammatory Phenotype in A549 Cells**

Given the frequent involvement of airways in LPI complications, we next addressed the impact of SLC7A7/y+LAT1 defect on the phenotype of an *in vitro* model of pulmonary cells, i.e., A549 human alveolar epithelial cells.

First, we performed a preliminary characterization of the transport routes for arginine in these cells, since the transporters involved in the transmembrane fluxes of the amino acid have not been described thus far in human alveolar models. The relative contribution of each transport component has been identified employing a strategy already used in other cell models (21, 30); results are shown in Figure 4. Arginine transport was comparable in the absence and in the presence of sodium (Figure 4A), thus excluding a significant contribution of sodium-dependent transport systems, such as B0. The addition of leucine inhibited arginine influx by more than 50% only in the presence of sodium, demonstrating the operation of system y+L and excluding a significant contribution of the sodium-independent system b0. In the presence of sodium, the addition of 2 mM lysine to leucine produced a further decrease of transport, thus indicating that also system y+ contributes to arginine uptake. Thus, in A549 cells, both systems y+ and y+L account for arginine transport, with the latter representing the predominant route (Figure 4B).

The relative contribution of the two alternative light subunits SLC7A6/y+LAT2 and SLC7A7/y+LAT1 to the activity of system y+L transporters was then investigated by selectively silencing one or the other gene (Figure 5). Data obtained indicate that the expression of both transporters was efficiently and specifically involved in the transmembrane fluxes of the amino acid.
reduced by siRNAs at both mRNA (Figures 5A,B) and protein level (Figure 5C); however, only the downregulation of SLC7A6 was able to slightly but significantly reduce arginine transport through system y+L (Figure 5D) and, in turn, to increase the intracellular content of the amino acid (Figure 5E). We can conclude that arginine availability in A549 cells is mainly regulated by SLC7A6/y+LAT2 activity. On the other hand, similarly to what observed in THP-1 macrophages (see Figure 1), the specific silencing of SLC7A7/y+LAT1 in A549 cells significantly induced the expression of IL1B and TNFA (Figure 5F), indicating that this protein modulates the inflammatory phenotype also of airway epithelial cells, with an effect that, even in this model, does not depend upon arginine content.

Next, we addressed whether SLC7A7/y+LAT1 was able to modulate A549 activation also in response to inflammatory stimuli. As shown in Figure 6, the mRNAs coding for CXCL8/IL8 and CCL5/RANTES chemokines was induced in a dose-dependent manner by exposure to IL1β (Figures 6A,B), with an EC50 roughly corresponding to 7 and 9 ng/ml for IL8 and RANTES, respectively. Interestingly, the downregulation of SLC7A7 markedly strengthened the stimulatory effect of 10 ng/ml IL1β on the expression and release of CCL5/RANTES by airway epithelial cells.
cells, while the levels of CXCL8/IL8 were induced to the same extent in scrambled and gene silenced cells (Figures 6C,D).

In light of all the results obtained, we finally verified whether the inflammatory phenotype of airway epithelial cells may be modulated by SLC7A7/y+LAT1 silencing in macrophages. To this aim, A549 cells were treated with the medium obtained by incubating THP-1 with either scrambled or SLC7A7 siRNA, both in the absence and in the presence of caspase-1 inhibitor z-WHED-FMK (CM). As shown in Figure 7, the medium obtained upon SLC7A7 silencing caused a marked increase of CCL5/RANTES, but not of CXCL8/IL8 expression in A549 cells; this induction was significantly prevented when epithelial cells were treated with CM obtained by silencing SLC7A7 in the presence of caspase-1 inhibitor. This latter had per se, no effect on chemokine expression when added to A549 cells in fresh, not CM (left panels).

**DISCUSSION**

The most credited pathogenetic model of LPI to date identifies key injurious stimuli in an abnormal intracellular entrapping of arginine due to the absence of a functional 4F2hc/y+LAT1 complex and, in turn, in an unbalanced metabolism of the amino acid through pathways that differ among cell types (3); in particular, an overproduction of nitric oxide by nitric oxide synthase 2 (NOS2) in macrophages is supposed to be central to the development of immune dysfunctions (31). However, experimental evidence confirming the specific role of the amino acid and its metabolites in the onset of pulmonary and immunological disorders in LPI are, thus far, missing.

Aim of the present contribution was, then, to explore the hypothesis of a new, thus far unknown role for SLC7A7/y+LAT1, able to explain LPI complications. In this context, we demonstrate here for the first time that SLC7A7 gene silencing in vitro causes the acquisition of an inflammatory phenotype in both human macrophages and airway epithelial cells and that this effect does not depend on intracellular arginine content.

Indeed, the incubation of THP-1 cells at increasing concentrations of arginine actually raised the intracellular content of the amino acid, without triggering either IL1β or TNFα production; conversely, the downregulation of y+LAT1 was sufficient...
per se to induce the expression of both proinflammatory cytokines, no matter arginine availability (Figure 2). Similarly, in A549 cells, SLC7A7 silencing significantly increased cytokines production without affecting intracellular arginine content (Figure 5); conversely, the inhibition of SLC7A6/γ+LAT2, which represents the major route for arginine in A549 cells, has no effect on cytokine release, despite it determine an increase of the amino acid inside the cells (Figures 4 and 5). These results point to a still unknown immunomodulatory function of γ+LAT1 transporter, which does not depend on arginine availability.

IL1β production is a multistep process involving the NF-κB-dependent transcription of the gene and the next cleavage of pro-interleukin by caspase-1 in inflammasome (29). In our hands, the activity of both NF-κB and caspase-1 was detectable even in control conditions, i.e., in scrambled silenced cells, hence explaining the basal release of inflammatory cytokines; since phorbol esters are known to actually activate inflammasome in THP-1 cells (32), this finding is likely ascribable to phorbol-12-myristate-13-acetate (PMA) employed for cell differentiation. Anyway, when SLC7A7/γ+LAT1 was silenced in macrophages, a more prominent nuclear translocation of p65 occurred, while the activity of caspase-1 was not altered; although the issue deserves to be better addressed, these results clearly ascribe the increase of IL1β secretion in silenced cells to an induction of NF-κB transcriptional activity, rather than to an hyper-activation of inflammasome. To this concern, the concomitant induction of TNFα mRNA reinforces the hypothesis of a key role for NF-κB in the effects observed upon SLC7A7 downregulation, since the same factor is notoriously responsible for the transcriptional regulation of this cytokine (33).

According to the results obtained, we speculate that γ+LAT1 protein, under physiological conditions, acts as a brake to restrain inflammation, possibly through the repression of molecular pathways regulating NF-κB signaling; then, defects of γ+LAT1...
protein in LPI macrophages could explain, at least in part, the mechanisms underlying immunological and hematological complications of the disease. In this context, the clinical features resembling hemophagocytic lymphohistiocytosis (HLH) in LPI could be, hence, ascribed to a spontaneous and persistent activation of macrophages consequent to the lack of a functional SLC7A7/y+LAT1 in these cells. Consistently, an alternative mechanistic pathway for HLH immunopathology has been, indeed, recently proposed, in which recurrent fever and severe systemic inflammation are supposed to be the consequence of genetic defects primary impairing macrophages activation; in particular, gain-of-function mutations in inflammasome genes of macrophages and dendritic cells are shown to sustain HLH development, bypassing the requirement of cytotoxic lymphocytes (14).

To the same extent, an increased production of cytokines by macrophages and epithelial cells upon SLC7A7 silencing could give reason of pulmonary complications in LPI: on the one hand, the spontaneous production of inflammatory cytokines by y+LAT1 defective epithelial cells may stimulate them in an autocrine activation; on the other hand, SLC7A7/y+LAT1 defect in both cell types could exacerbates lung inflammation in LPI through a macrophage-epithelial crosstalk. Pro-inflammatory cytokines, besides viruses, microbes, allergens, and other environmental factors, are, indeed, known to be key modulators of immune and inflammatory reactions in the lungs, through the activation of respiratory epithelial cells (34). Activated epithelium is an important source of both CC and CXC chemokines, such as CXCL8/IL8 and CCL5/RANTES: IL8 acts as a key mediator in neutrophil-mediated acute inflammation (35), while RANTES is a potent chemoattractant for blood monocytes, T cells, and eosinophils (36). As expected, both proteins were upregulated in A549 cells by IL1β (Figure 6), the most potent inducer of chemokines in the respiratory epithelium (37). However, despite the increased expression of pro-inflammatory cytokines in SLC7A7 silenced A549 cells (see Figure 5), no significant change in chemokine expression was observed (see Figure 6), excluding a major contribution of autocrine mechanisms in the activation of airway epithelium in LPI. Consistently, clinical evidences sustain a central role of circulating immune cells in the development of lung pathology (19). Interestingly, the incubation of alveolar cells with CM of silenced THP-1 caused a slight but significant induction of CCL5/RANTES that was mainly imputable to the release of IL1β by macrophages upon SLC7A7 downregulation (Figure 7). Under the same condition, the expression of CXCL8/IL8 remained unaltered; it is important, however, to point out that IL1β in CM at most corresponds to 150–200 pg/ml, which is far below the minimum effective concentration of the cytokine on IL8 expression (see Figure 6, for comparison).

The stimulatory effect of IL1β on CCL5/RANTES production and release by A549 cells was reinforced by SLC7A7 silencing (Figure 6), suggesting that y+LAT1 defective epithelial cells in LPI airways could be more responsive to inflammatory cytokines than healthy cells. Interestingly, increased levels of RANTES have been detected in serum (38) and skin lesions (39) of SLE patients, pointing to a role for this chemokine in the inflammatory processes observed in lupus and LPI-related lupus-like syndromes.

Overall, our findings sustain a pathogenic model for LPI pulmonary complications, according to which immune and airway epithelial cells would be engaged in a positive feedback circuit responsible for explosive inflammatory responses (Figure 8). More precisely, pro-inflammatory cytokines spontaneously secreted by y+LAT1-defective monocytes and epithelial cells are expected to hyper-stimulate RANTES production by y+LAT1-defective airway epithelial cells that, in turn, would continuously recruit circulating monocytes to the airways. Consistently, macrophage-epithelial communications in the lung are emerging as central to the regulation of alveolar physiological homeostasis as well as of alveolar host-pathogen interactions (40).

This kind of mechanisms, which are notoriously central to fibrogenic responses in the lung (41, 42), in the liver (43), as well in the kidney (44) could give reason of LPI-associated fibrosis and would identify LPI as an auto-inflammatory disease, hence laying...
the bases for the development of alternative pharmacological approaches based on the use of anti-cytokines drugs.

**AUTHOR CONTRIBUTIONS**

BMR and VD designed the experimental plan. FI, AB, and RV performed in vitro experiments; MM and MDL performed HPLC-tandem mass spectrometry analysis; PP, BR, and VD analyzed the results. BMR and VD wrote the paper. All authors read and approved the final manuscript.

**REFERENCES**

1. Borsani G, Bassi MT, Sperandeo MP, De Grandi A, Buoninconti A, Riboni M, et al. SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. *Nat Genet* (1999) 21(3):297–301. doi:10.1038/6815
2. Torrents D, Mykkanen J, Pineda M, Feliubadalo L, Estevez R, de Cid R, et al. Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene. *Nat Genet* (1999) 21(3):293–6. doi:10.1038/6809
3. Sebastio G, Sperandeo MP, Andria G. Lysinuric protein intolerance: reviewing concepts on a multisystem disease. *Am J Med Genet C Semin Med Genet* (2011) 157(1):54–62. doi:10.1002/ajmg.c.30287
4. Closs EI, Simon A, Vekony N, Rotmann A. Plasma membrane transporters for arginine. *J Nutr* (2004) 134(10 Suppl):2752S–9S. doi:10.1093/jn/134.10.2752S
5. Dave MH, Schulz N, Zecevic M, Wagner CA, Verrey F. Expression of heteromeric amino acid transporters along the murine intestine. *J Physiol* (2004) 558(Pt 2):597–610. doi:10.1113/jphysiol.2004.065037
6. Palacin M, Nunes V, Font-Llitjos M, Jimenez-Vidal M, Fort J, Gasol E, et al. The genetics of heteromeric amino acid acid transporters. *Physiology (Bethesda)* (2005) 20:112–24. doi:10.1152/physiol000051.2004
7. Terada T, Shimada Y, Pan X, Kishimoto K, Sakurai T, Doi R, et al. Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. *Biochem Pharmacol* (2005) 70(12):1756–63. doi:10.1016/j.bcp.2005.09.027
8. Broer S. Lysinuric protein intolerance: one gene, many problems. *Am J Physiol Cell Physiol* (2007) 293(2):C540–1. doi:10.1152/ajpcell.00166.2007
9. Kerem E, Elpelg ON, Shalev RS, Rosenman E, Bar Ziv Y, Branski D. Lysinuric protein intolerance with chronic interstitial lung disease and pulmonary cholesterol granulomas at onset. *J Pediatr* (1993) 123(2):275–8. doi:10.1016/S0022-3476(05)81703-2
10. Bagno G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. *Eur Respir Rev* (2015) 24(135):102–14. doi:10.1183/09059180.00003214
11. Valimahamed-Mitha S, Berteloot L, Ducoin H, Ottolenghi C, de Lonlay P, de Blic J. Lung involvement in children with lysinuric protein intolerance. *J Inherit Metab Dis* (2015) 38(2):257–63. doi:10.1007/s10545-014-9777-5
12. Doireau V, Fenneteau O, Duval M, Perelman S, Vilmer E, Touati G, et al. Lysinuric dibasic protein intolerance: characteristic aspects of bone marrow involvement. *Arch Pediatr* (1996) 3(9):877–80. doi:10.1016/0929-693X(96)87577-4
13. Duval M, Fenneteau O, Doireau V, Faye A, Emilie D, Yotnda P, et al. Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance. *J Pediatr* (1999) 134(2):236–9. doi:10.1016/S0022-3476(99)70423-3
14. Sepulveda FE, de Saint Basile G. Hemophagocytic syndrome: primary forms and predisposing conditions. *Curr Opin Immunol* (2017) 49:20–6. doi:10.1016/j.coi.2017.08.004
15. McClain KL. Clinical features and diagnosis of hemophagocytic lymphohistiocytosis. In: Post TW, editor. Waltham, MA: UpToDate Inc. (2018). Available from: http://www.uptodate.com (accessed on March 02, 2018).

**FUNDING**

This work was supported by Chiesi Farmaceutici, Parma, Italy (66DALLACHIESI).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.00508/full#supplementary-material.
16. Esteve E, Krug P, Hummel A, Arnoûx JB, Boyer O, Brassier A, et al. Renal involvement in lysinuric protein intolerance: contribution of pathology to assessment of heterogeneity of renal lesions. *Hum Pathol* (2017) 42(10):1690–9. doi:10.1016/j.humpath.2016.12.021

17. Mauhin W, Habarou E, Gobin S, Servais A, Brassier A, Grisel C, et al. Update on lysinuric protein intolerance, a multi-faceted disease retrospective cohort analysis from birth to adulthood. *Orphanet J Rare Dis* (2017) 12(1):3. doi:10.1186/s13023-016-0550-8

18. Lo MS, Tsokos GC. Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy. *Curr Opin Rheumatol* (2017) 30(2):222–8. doi:10.1097/BOR.0000000000000474

19. Santamaría F, Brancaccio G, Parenti G, Francalanci P, Squitieri C, Sebastio G, et al. Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance. *J Pediatr* (2004) 145(2):268–72. doi:10.1016/j.jpeds.2004.04.047

20. Barilli A, Rotoli BM, Visigalli R, Bussolati O, Gazzola GC, Kadija Z, et al. In lysinuric protein intolerance system y+L activity is defective in monocytes and in GM-CSF-differentiated macrophages. *Orphanet J Rare Dis* (2010) 5(1):32. doi:10.1186/1750-1172-5-32

21. Barilli A, Rotoli BM, Visigalli R, Bussolati O, Gazzola GC, Gatti R, et al. Impaired phagocytosis in macrophages from patients affected by lysinuric protein intolerance. *Mol Genet Metab* (2012) 105(4):585–9. doi:10.1016/j.ymgme.2012.01.008

22. Kurko J, Vaha-Mäkilä M, Tringham M, Tanner L, Paavanne-Huhtala S, Saarinen M, et al. Dysfunction in macrophage toll-like receptor signaling caused by an inborn error of cationic amino acid transport. *Mol Immunol* (2015) 67(2 Pt B):416–25. doi:10.1016/j.molimm.2015.07.006

23. Barilli A, Rotoli BM, Visigalli R, Bussolati O, Gazzola GC, Dall’asta V. Arginine transport in human monocytic leukemia THP-1 cells during macrophage differentiation. *J Leukoc Biol* (2011) 90(2):293–303. doi:10.1189/jlb.0910510

24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* (2001) 25(4):402–8. doi:10.1006/meth.2001.1262

25. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y. CATs and lysinuric protein intolerance system y+ activities are equal in normal human monocytes and transepithelial delivery of NOS inhibitors. *FASEB J* (2004) 18(4):526–31. doi:10.1096/ajrccm.18.4.2868

26. Rotoli BM, Bussolati O, Sala R, Barilli A, Talarico E, Gazzola GC, et al. INFgamma stimulates arginine transport through system y+L in human monocytes. *FEBS Lett* (2004) 571(1–3):177–81. doi:10.1016/j.febslet.2004.06.086

27. Ingoglia F, Visigalli R, Rotoli BM, Barilli A, Riccardi B, Puccini P, et al. Human macrophage differentiation induces OCTN2-mediated L-carnitine transport through stimulation of mTOR-STAT3 axis. *J Leukoc Biol* (2017) 101(3):665–74. doi:10.1189/jlb.1A0616-254R

28. Gazzola GC, Dall’asta V, Franchi-Gazzola R, White MF. The cluster-tray method for rapid measurement of solute fluxes in adherent cultured cells. *Anal Biochem* (1981) 115(2):368–74. doi:10.1016/0003-2697(81)90019-1

29. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. *Nat Med* (2015) 21(7):677–87. doi:10.1038/nm.3893

30. Rotoli BM, Bussolati O, Sala R, Gazzola GC, Dall’asta V. The transport of cationic amino acids in human airways cells: expression of system y+L activity and transepithelial delivery of NOS inhibitors. *FEBS Let* (2005) 19(7):810–2. 10.1096/f1.04-2924J

31. Ogier de Baulny H, Schiff M, Dionisi-Vici C. Lysinuric protein intolerance (LPI): a multi organ disease by far more complex than a classic urea cycle disorder. *Mol Genet Metab* (2012) 106(1):12–7. doi:10.1016/j.ymgme.2012.02.010

32. Kong F, Ye B, Cao J, Cai X, Lin L, Huang S, et al. Curcumin represses NLRP3 inflammasome activation via TLR4/MyD88/NF-kappaB and P2X7R signaling in PMA-induced macrophages. *Front Pharmacol* (2016) 7:369. doi:10.3389/fphar.2016.00369

33. Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. *Crit Rev Eukaryot Gene Expr* (2010) 20(2):87–103. doi:10.1615/CritRevEukaryotGeneExpr.v20i2.10

34. Schleimer RP, Kato A, Kern R, Kuperman D, Avila PC. Epithelium: at the interface of innate and adaptive immune responses. *J Allergy Clin Immunol* (2007) 120(6):1279–84. doi:10.1016/j.jaci.2007.08.046

35. Sehmi R, Cromwell O, Wardlaw AJ, Mosqel R, Kay AB. Interleukin-8 is a che- mo-attractant for eosinophils purified from subjects with a blood eosinophilia but not from normal healthy subjects. *Clin Exp Allergy* (1993) 23(12):1027–36. doi:10.1111/j.1365-2222.1993.tb0295.x

36. Calley FJ, Pennycook AM, Tregoning JS, Dodd JS, Wald G, Wells TN, et al. Role of CCL5 (RANTES) in viral lung disease. *J Virol* (2006) 80(16):8151–7. doi:10.1128/JVI.00496-06

37. Brabcova E, Kolesar I, Thorburn E, Striz I. Chemokines induced in human respiratory epithelial cells by IL-1 family of cytokines. *Folia Biol* (Prague) (2014) 60(4):180–6.

38. Lu MM, Wang J, Pan HF, Chen GM, Li J, Cen H, et al. Increased serum RANTES in patients with systemic lupus erythematosus. *Rheumatol Int* (2012) 32(5):1231–3. doi:10.1186/1750-1172-5-1086-x

Copyright © 2018 Rotoli, Barilli, Visigalli, Ingoglia, Miletti, Di Lucia, Riccardi, Puccini and Dall’asta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.